Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IgT Cells for the Treatment of Glioblastoma Multiforme
NCT03170141Phase 1Terminated
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- May 2017
- Primary completion
- Jul 2026
- Modality
- Gene Editing, Gene Silencing, Allogeneic CAR-T
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Antigen-specific IgT cells in glioblastoma multiforme (GBM), sponsored by Shenzhen Geno-Immune Medical Institute. Primary endpoint: Safety of infusion of autologous IgT cells with cyclophosphamide and fludarabine at 1 year. Started May 2017; status: terminated.
02
Drugs
Antigen-specific IgT cells
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT03170141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03170141.